3-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-6-((6-(1,3-thiazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one | 1268515-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-6-((6-(1,3-thiazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one
• 英文别名: 3-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-6-{[6-(1,3-thiazol-4-yl)pyridine-3-yl]methyl}benzo[h]quinazolin-4(3H)-one；3-[(3R,4S)-3-hydroxyoxan-4-yl]-6-[[6-(1,3-thiazol-4-yl)pyridin-3-yl]methyl]benzo[h]quinazolin-4-one
• CAS: 1268515-83-8
• 化学式: C₂₆H₂₂N₄O₃S
• 分子量: 470.552
• InChiKey: XMBHQVIWOZLMNN-ZEQRLZLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-<β-trans-(N,N-dimethylamino)ethenyl>-1-nitronaphthalene 在 copper(l) iodide 、 四(三苯基膦)钯 、 二(三叔丁基膦)钯 、 palladium on activated charcoal 盐酸 、 potassium permanganate 、 水 、 氢气 、 溴 、 potassium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 、 乙腈 、 叔丁醇 为溶剂， 140.0 ℃ 、101.33 kPa 条件下， 反应 77.5h， 生成 3-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-6-((6-(1,3-thiazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one
  参考文献：
  名称：

  [EN] PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DE RÉCEPTEUR M1 DE TYPE PYRANYL-ARYL-MÉTHYL-BENZOQUINAZOLINONE

  摘要：

  本发明涉及式（I）的吡喃基芳基甲基苯并喹唑啉酮化合物，这些化合物是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。

  公开号：

  WO2011025851A1

文献信息

• PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Kuduk Scott D.

  公开号：US20120157438A1

  公开（公告）日：2012-06-21

  The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡喃基苯基甲基苯并喹唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包括该化合物的制药组合物，以及使用该化合物和组合物治疗M1受体介导的疾病。
• Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09260418B2

  公开（公告）日：2016-02-16

  The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡喃基芳基甲基苯并喹唑啉酮化合物，它们是M1受体正向变构调节剂，可用于治疗与M1受体有关的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括该化合物的制药组合物，以及在治疗由M1受体介导的疾病中使用该化合物和组合物的方法。
• Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
  申请人：Kuduk Scott D.

  公开号：US08846702B2

  公开（公告）日：2014-09-30

  The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡喃基苯基甲基苯并喹唑醌酮化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的制药组合物，以及使用该化合物和组合物治疗由M1受体介导的疾病。
• Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140364395A1

  公开（公告）日：2014-12-11

  The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的吡喃基苯甲基苯并喹唑酮化合物，其为M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的药物组合物，以及使用该化合物和组合物治疗M1受体介导的疾病的方法。
• US8846702B2
  申请人：——

  公开号：US8846702B2

  公开（公告）日：2014-09-30